viernes, 13 de noviembre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 20, 2026

Target Corp (TGT) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic ...

View original at finance.yahoo.com
Target Corp (TGT) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic ... This article first appeared on GuruFocus. Net Sales: $25.4 billion, a 6.7% increase from last year…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • SG&A expenses increased due to higher investments in payroll, training, and marketing

    60% confidence
  • Gross margin rate was 29%, an improvement of 80 basis points from the previous year

    60% confidence
  • Broader operating environment remains uncertain with potential headwinds from consumer sentiment and economic conditions

    60% confidence
  • Categories like home and apparel have sales still below 2024 levels, indicating areas that need further improvement

    60% confidence
  • Operating margin rate of 4.5% was 80 basis points higher than last year's adjusted rate of 3.7%

    60% confidence
  • Digital channel first-party sales grew nearly 9%, with same-day delivery increasing by more than 27%

    60% confidence
  • Target Plus achieved nearly 60% growth in first quarter GMV

    60% confidence
  • Company is executing a multiyear strategy to revamp merchandising and store operations including new leadership roles

    60% confidence
  • Company expects more challenging prior-year comparisons and potential cost headwinds in the first half of the year

    60% confidence
  • 7 new stores opened in Q1 including the 2,000th location, with plans to open more than 30 this year

    60% confidence
  • Net sales were $25.4 billion, a 6.7% increase from last year

    60% confidence
  • Capital expenditures were approximately $1 billion in Q1 with full-year expectation of about $5 billion

    60% confidence
  • Dividend payments were $516 million in Q1, with a 1.8% increase in per share dividend

    60% confidence
  • SG&A expense rate of 21.9% was more than 2 percentage points higher than last year's rate of 19.3%

    60% confidence
  • Comparable sales grew 5.6%, driven by a 4.4% increase in traffic

    60% confidence
  • Net Promoter Scores and satisfaction metrics reached three-year highs following new guest experience initiatives

    60% confidence
  • Growth was broad-based across both stores and digital channels, with notable increases in all six core merchandise categories

    60% confidence
  • Adjusted EPS of $1.71 was 32% higher than prior year adjusted EPS

    60% confidence

Data points we hold from this source

Target Corporation · total store count2000 stores
Target Corporation · same day delivery growth27 percent
Target Corporation · traffic growth4.4 percent
Target Corporation · sga rate21.9 percent
Target Corporation · operating margin4.5 percent
Target Corporation · operating margin prior year adjusted3.7 percent
Target Corporation · margin29.0 percent
Target Corporation · new stores opened7 stores
Target Corporation · gross margin yoy change0.80 percent
Target Corporation · sga rate prior year19.3 percent
Target Corporation · digital first party sales growth9 percent
Target Corporation · dividend payment516 USD
Target Corporation · capex1.0 USD
Target Corporation · comparable sales growth5.6 percent
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,577 documentos fuente archivados
Consulta estos datos → isubstrate.com